Gufic's journey in the field of pharmaceuticals thus far has an underlying theme oftimely evolution and adaption to the evolving healthcare sector. The past year was alitmus test of all our learnings.
The pandemic has made people more concerned about their health. People have realisedthe importance of health and wellness which has become an integral aspect of themodern-day lifestyle in the post pandemic world. The Covid-19 pandemic created 'thebiggest seismic shift' taking health and immunity to the centre stage. I am certain thatthis is not a passing fad but a trend that will define the journey of the healthcaresector in the coming decade. This trend will have a far and wide ripple effect on areassuch innovation of preventive and curative therapies infrastructure of healthcarefacilities and easy access to holistic & affordable healthcare services. I believeGufic is well positioned to contribute and benefit from some of these decade definingtrends.
The various government initiatives to the pharmaceutical and biotechnology industrywill usher in a new era of research development and innovation oriented towards creatingnew chemical entities and biosimilars. This will broaden India's positioning in the globalhealthcare market from a cost-effective manufacturer to a class leading innovator.Government of India's timely initiatives to promote the indigenisation of the ActivePharmaceutical Ingredient (API) and Key Starting Material (KSM) industry will ensure thatwe are not bound by the frailties of international markets for these critical inputs. Iforesee that this is only the tip of the iceberg in terms of indigenisation andglobalisation of the Indian Pharmaceutical and Biotechnology industry. These initiativeswill encourage import substitution of medicines with more affordable made in Indiamedicines and it will be Gufic's endeavour to take science to society affordably andeffectively.
Our core strength of lyophilisation that is delivered to the market through our 3strategic business channels - domestic branded unit Contract Manufacturing Organizationsunit and international market unit - constitute our near-term growth levers. We aim tofortify our position in the injectable segment through increasing our capacities (ongoingcapex at Indore Madhya Pradesh) introducing new molecules (some are first in India)ushering new technologies in drug delivery systems (dual chamber bags dual chambersyringes depot injections etc) and venturing into new regulated and rest of the worldmarkets. We have the vision strategy and team to effectively grind the near-term .4growth levers.
As the global pharmaceutical playbook unravels we see competition in traditionalmolecules and markets. As a company with long lineage in branded products encapsulated byour DNA of scientific research has led to several industry firsts we continue to planahead and invest in businesses of the future. These include deepening our presence inbotulinum toxin market with the help of M/s. Prime Bio Inc US based Company anddiscovery and development of immuno-oncology therapy with our partner M/s. Selvax Pty Ltdan Australian Company and leverage the new biological technology platform to developpreventive and curative medical care for fatal infections. Together we see these tocatalyse our next orbit of growth.
As I look back at the year; I am proud of our fellow Guficians for their relentlesssupport and commitment to Gufic's vision. I express my deepest gratitude to my fellowBoard Members for their guidance and support and I am deeply indebted to all ourstakeholders and shareholders for the belief bestowed in Gufic.
For Gufic Biosciences Limited
Jayesh P Choksi
Chairman & Managing Director